AI assistant
Corvus Pharmaceuticals, Inc. — Director's Dealing 2017
Dec 15, 2017
32755_dirs_2017-12-15_5247be77-f324-45c7-a343-4396b84ffe22.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2017-12-13
Reporting Person: LEA LEIV (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-12-13 | Stock Option (Right to Buy) | $10.60 | A | 40000 | Acquired | 2027-12-13 | Common Stock (40000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock, $0.0001 par value | 149206 | Indirect |
Footnotes
F1: A portion of these shares is subject to a right of repurchase held by the Issuer.
F2: These shares are held by Leiv Lea and Deborah Karlson, Trustees of the Karlson Lea Family Trust UTA dated February 11, 1998 (the "Karlson Lea Trust"). Mr. Lea has shared voting, investment and dispositive power over the shares held by the Karlson Lea Trust.
F3: The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from December 13, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.